The Atlantic Common Drug Review (ACDR) committee reviewed TOBITM on two occasions, in 2007 and 2011. Both resulted in recommendations that TOBITM should not be reimbursed by public drug plans in the Atlantic provinces.
The Newfoundland Pharmaceutical Services Division have made a request to the Canadian Agency for Drugs and Technologies in Health (CADTH) to complete a Rapid Response Service review with respect to the comparative evidence for TOBITM and inhaled tobramycin. This is being undertaken to provide a second independent assessment which could impact the ACDR’s negative recommendation regarding reimbursement of TOBITM.
Although there is not yet a precise timeframe for the completion of this review, Cystic Fibrosis Canada will monitor progress closely and keep you informed.